Monday, December 23, 2024 | 02:57 AM ISTEN Hindi

Home / Companies / News / USFDA approves AstraZeneca's combo treatment for lung cancer patients

USFDA approves AstraZeneca's combo treatment for lung cancer patients

The combo treatment has been approved in the United States for adult patients with extensive-stage small cell lung cancer, the company said

Initiate suitable prosecution steps against AstraZeneca management, pleads FMRI

Premium

Small cell lung cancer is a highly aggressive, fast-growing form of cancer that typically recurs and progresses rapidly despite initial response to chemotherapy

Reuters

1 min read Last Updated : Mar 30 2020 | 3:13 PM IST

The U.S. Food and Drug Administration approved AstraZeneca Plc's combo treatment for a form of lung cancer in previously untreated patients, the drugmaker said on Monday.

The combo treatment has been approved in the United States for adult patients with extensive-stage small cell lung cancer, the company said.

The approval was based on results from a late-stage study in which the treatment showed a statistically significant improvement in overall survival in lung cancer patients when compared to standard of care, the company said.

ALSO READ: This is a once-in-a-decade opportunity to invest in equities: S Naren

Small cell lung cancer

Topics : USFDA AstraZeneca Pharma USFDA approves lung cancer drug

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in